Anaphylaxis will not reliably go away on its own, and waiting for it to pass can be fatal. Without treatment, anaphylaxis often progresses to respiratory collapse, with roughly half of anaphylaxis-related deaths occurring within the first hour of symptom onset. The body does have built-in mechanisms that can slow the release of inflammatory chemicals, but these processes are too slow and unreliable to count on during a life-threatening reaction.
Why the Body Can’t Stop It Fast Enough
During anaphylaxis, immune cells release a massive flood of inflammatory chemicals all at once. Your body does have natural braking systems for this process. Specialized ion channels in these immune cells eventually shut down the calcium signaling that drives the chemical release, and enzyme systems work to reverse the cascade. But these built-in brakes were designed for small, localized immune responses, not the system-wide surge that defines anaphylaxis.
The result is a race between your body’s ability to rein in the reaction and the damage the reaction is doing in real time. Blood pressure can plummet as blood vessels dilate wide open. Airways can swell shut. The median time from symptom onset to cardiac or respiratory arrest in fatal cases is less than 30 minutes. That’s not enough time for the body’s own shutdown mechanisms to catch up.
What Epinephrine Actually Does
Epinephrine is the only treatment that directly reverses what’s happening during anaphylaxis. It tightens blood vessels to restore blood pressure, relaxes the muscles around the airways to reopen breathing, and strengthens the heart’s contractions. It works within minutes, which is why guidelines stress giving it as early as possible rather than waiting to see if symptoms improve.
About 90% of anaphylaxis events respond to a single dose of epinephrine. The remaining cases may need two, three, or more doses, and a small number of reactions are considered refractory, meaning they resist treatment and require hospital-level interventions like IV medications and aggressive fluid support.
Symptoms Can Return After They Seem to Resolve
Even after successful treatment, anaphylaxis can come back. This is called a biphasic reaction: symptoms resolve, then return hours later without any new exposure to the allergen. In one study of 202 patients, about 9% experienced a biphasic reaction. Of those, 78% had the second wave within 12 hours, though rare cases occurred more than 48 hours later.
The second reaction is usually milder. Only about 1% of patients in that study had a biphasic reaction severe enough to cause dangerous drops in blood pressure or oxygen levels. Still, the possibility is the reason hospitals keep you for observation after treating anaphylaxis.
Interestingly, neither steroids nor antihistamines have been shown to prevent biphasic reactions. Systematic reviews have found no evidence that steroids reduce reaction severity or stop the second wave, and antihistamines don’t reduce biphasic rates either. Even epinephrine treatment during the initial reaction doesn’t appear to lower the odds. The current approach is simply to watch and wait in a medical setting where a second reaction can be treated quickly.
How Long You’re Monitored Afterward
UK guidelines recommend a risk-based approach to observation time after anaphylaxis resolves. If you responded well to a single dose of epinephrine within 30 minutes and your symptoms fully cleared, you may be discharged after 2 hours of observation, provided you already carry an epinephrine auto-injector and know how to use it.
If you needed two doses of epinephrine, or you’ve had a biphasic reaction in the past, the minimum observation jumps to 6 hours. For more severe cases, including those requiring more than two doses, those involving serious breathing difficulty, or those where the allergen may still be absorbing (like a slow-release medication), at least 12 hours of monitoring is recommended.
Will the Underlying Allergy Go Away Over Time?
This depends entirely on the trigger. Some allergies, particularly to milk and egg, commonly resolve during childhood, though not as quickly as doctors once assumed. In U.S. studies, about 50% of children with milk allergy outgrew it by age 5, and roughly 79% by age 16. For egg allergy, about 50% of children develop tolerance by age 3 in U.S. populations, with around 68% outgrowing it by 16.
Peanut allergy is far more persistent. Only about 22% of children outgrow it by age 4, and resolution after adolescence is uncommon. Tree nut allergies are even stickier, with only 9 to 14% of children developing tolerance over time. Fish and shellfish allergies also tend to persist into adulthood.
Recent research suggests that even the “easier” allergies like milk and egg are persisting longer than they used to, with more children carrying these allergies into young adulthood. The reasons for this shift aren’t well understood. People with asthma face higher risk of fatal anaphylaxis regardless of their specific trigger, making it especially important for them to carry epinephrine and have an action plan even if they expect to eventually outgrow the allergy.
For adults who develop a new allergy, the odds of spontaneous resolution are generally lower than for children. An allergy that first appears in adulthood, particularly to nuts, fish, or shellfish, is likely to be lifelong.